ClinicalTrials.gg
TerminatedNCT01365468Updated May 12, 2016Results posted

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

A Phase 2 interventional study of Everolimus (RAD001) in Plexiform Neurofibroma Associated With Neurofibromatosis Type 1, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in Israel. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2016-05-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Poor patients' accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Study summary

This study was to evaluate the antitumor activity and safety of RAD001 in patients with Plexiform neurofibromas (PN) associated with Neurofibromatosis Type 1 (NF1).

The aim of the study was to :

  1. determine whether RAD001, administrated orally daily on a continuous dosing schedule might:

    1. Increases time to disease progression (TTP) based on volumetric MRI measurements in children and adults with NF1 in inoperable documented progressive PN (stratum 1).
    2. Results in objective radiographic responses based on volumetric MRI measurements in children and adults with NF1 and inoperable PN in the absence of documented radiographic progression at the trail entry (stratum
  2. To evaluate the tolerability and toxicity of chronic RAD001 administration in this patient population as assessed by the NCI Common Toxicity Criteria, version 4.0.
Read the detailed description

Approximately 20 patients were to be enrolled to receive everolimus in an open label manner. A total of 9 patients were enrolled to either Stratum 1 or Stratum 2.

The study was open for enrollment up to 2 years. Because the target enrollment was not achieved in this period, study was terminated with less patient than planned.

02

Conditions studied

  • Plexiform Neurofibroma Associated With Neurofibromatosis Type 1

Keywords

  • RAD001,
  • Everolimus,
  • Plexiform Neurofibroma,
  • Neurofibromatosis Type 1
03

In context

Neurofibroma, Plexiform

63 studies on the registry are indexed under Neurofibroma, Plexiform; 19 are open to participants now.

This study's enrollment of 9 is below the median of 36 across 43 interventional studies indexed under Neurofibroma, Plexiform.

Browse Neurofibroma, Plexiform studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinically definite diagnosis of NF1 according to the NIH consensus conference criteria.
  2. Patients must have PN that have the potential to cause significant morbidity, such as lesions that could compromise the airway or the great vessels, lesions that could cause nerve compression, lesions that could result in major deformity or significant cosmetic problems
  3. : patient must have at least one measurable PN amenable to volumetric MRI analysis.

Exclusion criteria

Exclusion Criteria:

  1. Chronic treatment with systemic or another agent.
  2. Evidence of an active optic glioma, malignant glioma, malignant peripheral nerve sheath tumor, or other cancer requiring treatment with chemotherapy or radiation therapy.
  3. Clinical evidence of significantly impaired lung function
  4. Pregnancy or breast feeding.
  5. Prior therapy with mTOR inhibitors (e.g.sirolimus, temsirolimus, everolimus).
  6. No for MRI assessments

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Everolimus (RAD001)

    enrolled patients received everolimus (RAD001) in an open label manner. Recommended starting dose of everolimus depend on body surface area, starting from 2.5 mg once daily to 7.5 mg once daily.

    Drug: Everolimus (RAD001)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Disease Progression (TTP) Based on Change in Volumetric MRI Measurements in Children and Adults (In Stratum I Only)

    This endpoint was planned to be analyzed for only Stratum 1 patients. Progression of disease defined as a ≥ 20% increase in the volume (by volumetric MRI) of at least one of the index plexiform neurofibromas (PN) compared to the pretreatment volume measured prior to the start of the current treatment phase.

    Time frame: Screening, after course #6, #12, #18, #24, End of Treatment(1 course=28days)

  2. Number of Patients With Objective Radiographic Responses Based on Volumetric MRI Measurements (In Stratum 2 Only)

    Response was assessed at the time that a follow up volumetric MRI scan is performed (after course 6 and then every 6 months and at the end of treatment). * Complete response (CR): complete resolution of all measurable or palpable PN for ≥ 28days and no appearance of new lesions. * Partial response (PR): A ≥ 20% reduction in the sum of the volume of all index PN lesions for ≥ 28days. * Stable disease (SD): A \< 20% increase and \< 20% decrease in the sum of the volume of all index PN lesions for ≥ 28days.

    Time frame: Screening, after course #6, then every 6 months and end of treatment(1 course=28days)

  3. Number of Patients With Adverse Events Assessed by Common Toxicity Criteria for Adverse Events (CTCAE) V.04

    Adverse events were assessed according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0. If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, and life-threatening, corresponding to grades 1 - 4 respectively, were used. CTCAE grade 5 (death) was not used in this study.

    Time frame: From the time ICF was signed until 28 days after End of Treatment (up to a maximum of 25 months)

Other outcomes

  1. Number of Patients With Clinical Response

    Clinical response is defined as improvement of function, performance status, or decrease in PN related pain persisting for at least 28 days on treatment.

    Time frame: Screening, Day 1, after course #3, #6, #12, #18, #24, End of Treatment (1 course = 28 days)

  2. Physician's Global Assessment of Clinical Condition (PGA) of Skin Lesions

    The Physician"s Global Assessment of Clinical Condition (PGA) is a 7-point grading scale for the investigator's assessment of the overall extent of improvement or worsening of the patient"s skin disease as compared to baseline. Responses must be confirmed by at least two assessments separated in time by at least 4 weeks. The grading ranges from 0 to 6; 0 is Completely clear where as 6 is for worse condition. A complete clinical response (CCR) requires a grading of 0 indicating the absence of disease (histological confirmation is not required). Grades 1, 2, and 3 constitute partial response, indicating improvement of at least 50 percent, but less than 100 percent improvement.

    Time frame: Screening, after course #3, #6, #12, #18, #24, End of Treatment (1 course = 28 days)

07

Results

Posted May 12, 2016
Limitations and caveats
Study got terminated because of poor patient's accrual.

Participant flow

Participant flow — Overall Study
MilestoneStratum 1Stratum 2
Started45
Completed05
Not completed40
Withdrew: Physician decision10
Withdrew: Disease progression10
Withdrew: Lost to follow-up20

Outcome measures

PrimaryTime to Disease Progression (TTP) Based on Change in Volumetric MRI Measurements in Children and Adults (In Stratum I Only)

This endpoint was planned to be analyzed for only Stratum 1 patients. Progression of disease defined as a ≥ 20% increase in the volume (by volumetric MRI) of at least one of the index plexiform neurofibromas (PN) compared to the pretreatment volume measured prior to the start of the current treatment phase.

Time frame:
Screening, after course #6, #12, #18, #24, End of Treatment(1 course=28days)
Reported as:
Median · Days
Time to Disease Progression (TTP) Based on Change in Volumetric MRI Measurements in Children and Adults (In Stratum I Only)
DaysStratum 1
Time to Disease Progression (TTP) Based on Change in Volumetric MRI Measurements in Children and Adults (In Stratum I Only)NA (NA to NA)
PrimaryNumber of Patients With Objective Radiographic Responses Based on Volumetric MRI Measurements (In Stratum 2 Only)

Response was assessed at the time that a follow up volumetric MRI scan is performed (after course 6 and then every 6 months and at the end of treatment). * Complete response (CR): complete resolution of all measurable or palpable PN for ≥ 28days and no appearance of new lesions. * Partial response (PR): A ≥ 20% reduction in the sum of the volume of all index PN lesions for ≥ 28days. * Stable disease (SD): A \< 20% increase and \< 20% decrease in the sum of the volume of all index PN lesions for ≥ 28days.

Time frame:
Screening, after course #6, then every 6 months and end of treatment(1 course=28days)
Reported as:
Number · Patients
Number of Patients With Objective Radiographic Responses Based on Volumetric MRI Measurements (In Stratum 2 Only)
PatientsStratum 2
Complete Response0
Partial Response0
Stable Disease5
PrimaryNumber of Patients With Adverse Events Assessed by Common Toxicity Criteria for Adverse Events (CTCAE) V.04

Adverse events were assessed according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0. If CTCAE grading does not exist for an adverse event, the severity of mild, moderate, severe, and life-threatening, corresponding to grades 1 - 4 respectively, were used. CTCAE grade 5 (death) was not used in this study.

Time frame:
From the time ICF was signed until 28 days after End of Treatment (up to a maximum of 25 months)
Reported as:
Number · Patients
Number of Patients With Adverse Events Assessed by Common Toxicity Criteria for Adverse Events (CTCAE) V.04
PatientsStratum 1Stratum 2
At least one Grade 1 AE45
At least one Grade 2 AE45
At least one Grade 3 AE10
At least one Grade 4 AE10
Other pre-specifiedNumber of Patients With Clinical Response

Clinical response is defined as improvement of function, performance status, or decrease in PN related pain persisting for at least 28 days on treatment.

Time frame:
Screening, Day 1, after course #3, #6, #12, #18, #24, End of Treatment (1 course = 28 days)

No measurements were reported for this outcome.

Other pre-specifiedPhysician's Global Assessment of Clinical Condition (PGA) of Skin Lesions

The Physician"s Global Assessment of Clinical Condition (PGA) is a 7-point grading scale for the investigator's assessment of the overall extent of improvement or worsening of the patient"s skin disease as compared to baseline. Responses must be confirmed by at least two assessments separated in time by at least 4 weeks. The grading ranges from 0 to 6; 0 is Completely clear where as 6 is for worse condition. A complete clinical response (CCR) requires a grading of 0 indicating the absence of disease (histological confirmation is not required). Grades 1, 2, and 3 constitute partial response, indicating improvement of at least 50 percent, but less than 100 percent improvement.

Time frame:
Screening, after course #3, #6, #12, #18, #24, End of Treatment (1 course = 28 days)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stratum 1—1/4 (25%)4/4 (100%)
Stratum 2—0/5 (0%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventStratum 1Stratum 2
HypersensitivityImmune system disorders1/40/5
Most frequent other events
Showing 10 of 57
Most frequent other events
EventStratum 1Stratum 2
HeadacheNervous system disorders3/44/5
Influenza like illnessGeneral disorders3/41/5
Ear painEar and labyrinth disorders2/40/5
DiarrhoeaGastrointestinal disorders2/40/5
DysphagiaGastrointestinal disorders2/40/5
FatigueGeneral disorders2/42/5
Mucosal inflammationGeneral disorders2/42/5
Pain in extremityMusculoskeletal and connective tissue disorders2/40/5
RashSkin and subcutaneous tissue disorders2/40/5
Abdominal painGastrointestinal disorders1/42/5

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Stratum 1Stratum 2Total
Mean22.7 ± 14.316.9 ± 9.819.5 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Stratum 1Stratum 2Total
Female314
Male145
08

Study locations

2 sites
  • Novartis Investigative Site
    Tel-Aviv, 6423906, Israel
  • Novartis Investigative Site
    Tel-Hashomer, 52621, Israel
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2011
First posted
Jun 3, 2011
Start
Apr 2012
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
May 12, 2016
Last update
May 12, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01365468
Responsible party
Sponsor
First posted
Jun 3, 2011
Start date
Apr 2012
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
May 12, 2016
Last update
May 12, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion